{"id":14113,"date":"2026-06-01T21:06:00","date_gmt":"2026-06-01T19:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=bd1b312e4e8f273c706c935dc830cf18"},"modified":"2026-06-01T21:06:00","modified_gmt":"2026-06-01T19:06:00","slug":"abl-diagnostics-presents-its-financial-roadmap-and-growth-outlook-for-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=14113","title":{"rendered":"ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<b><i>Full-year 2026 revenue target set at \u20ac12.27 million, delivering an exceptional +76.5% growth compared to 2025<\/i><\/b><\/li>\n<li>\n<b><i>Historic shift in scale driven by the full-year impact of growth drivers (FTD Kits up +353%, Vela at \u20ac1.57m, and CDL at \u20ac2.48m)<\/i><\/b><\/li>\n<li>\n<b><i>Strong commercial visibility supported by robust business momentum during the first months of the fiscal year<\/i><\/b><\/li>\n<\/ul><p>WOIPPY, France--(BUSINESS WIRE)--Regulatory\u00a0News:<\/p><p>\nABL Diagnostics (Paris:ABLD) (Euronext Paris \u2013 Compartment B \u2013 ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample management, today announces its precise full-year revenue targets for the fiscal year ending December 31, 2026 (Guidance).<\/p><p>\n<i>\"The consolidated operational indicators for the 2026 fiscal year confirm a historic shift in scale for ABL Diagnostics. With a revenue target of \u20ac12.27 million, representing growth of over 76%, we are reaping the benefits of the technology integration strategy initiated in 2025. The remarkable performance of the UltraGene range (FTD assets), combined with the massive contribution of our exclusive distribution agreements with Vela Diagnostics and CDL Pharma, validates our business model as a global player in in vitro diagnostics,\"<\/i> stated Dr. Chalom Sayada, CEO of ABL Diagnostics. <i>\"Our strong commercial visibility and the recurrence of our business workflows allow us to confirm this full-year trajectory with high confidence.\"<\/i><\/p><p>\n<b>2026 Revenue Targets and Outlook by Business Segment<\/b><\/p><p>\nBased on its commercial management roadmap derived from underlying operational data, ABL Diagnostics targets total revenue of \u20ac12,265k for the full-year 2026, compared to \u20ac6,950k in 2025, representing a targeted overall growth of +76.5%.<\/p><p>\nThe breakdown by business segment is as follows:<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>En milliers d'euros (k\u20ac)<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>R\u00e9alis\u00e9 2025<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Objectif Atterrissage 2026<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Variation vis\u00e9e<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>% du CA 2026<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwwidth20 bwpadl1 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Kits &amp; Reagents<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n3 170<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5 798<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+82,9 %<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n47,3 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwwidth20 bwpadl1 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Software Solutions<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n1 057<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n1 211<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+14,6 %<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n9,9 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor1 bwwidth20 bwpadl1 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Services &amp; Others<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2 723<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5 256<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+93,0 %<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n42,9 %<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwwidth20 bwpadl1 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b><\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6 950<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n12 265<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+76,5 %<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwnowrap\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n100,0 %<\/p><\/td><\/tr>\n<\/table><p>\n<b>Analysis of Growth Momentum by Segment<\/b><\/p><p>\n<span class=\"bwuline\">1. Kits &amp; Reagents Segment: A major acceleration of +82.9%<\/span><\/p><p>\nThis historical business segment is crossing a milestone to reach \u20ac5,798k, driven by two complementary engines:<\/p><ul class=\"bwlistdisc\">\n<li>\nUltraGene Range (syndromic qPCR, ex-Fast Track Diagnostics): Acting as a true catalyst for the fiscal year, this business line shows exponential growth of +353.5% to reach \u20ac1,582k at year-end 2026.<\/li>\n<li>\nHIV Business Line: The Company's historical and recurring foundation maintains a highly robust momentum with expected growth of +132.0% to settle at \u20ac3,906k.<\/li>\n<\/ul><p>\n<span class=\"bwuline\">2. Services &amp; Others Segment: Revenues nearly doubling (+93.0%)<\/span><\/p><p>\nStrategic distribution agreements implemented in 2025 are delivering their full commercial potential on a full-year basis, reaching \u20ac5,256k:<\/p><ul class=\"bwlistdisc\">\n<li>\nCDL Pharma: The integration of clinical research support activities contributes massively to the extent of \u20ac2,482k (+289.7%).<\/li>\n<li>\nVela Diagnostics: Trading activities initiated in the second half of 2025 confirm a rapid ramp-up, contributing \u20ac1,565k over the 2026 fiscal year (+457.2%).<\/li>\n<\/ul><p>\n<span class=\"bwuline\">3. Software Solutions Segment: Steady organic growth (+14.6%)<\/span><\/p><p>\nThe software business line (DeepChek<sup>\u00ae<\/sup>, ViroScore, MicrobioChek, and NADIS) totals \u20ac1,211k, supported notably by the resilience of the NADIS hospital management software, which grows by +117.2% to reach \u20ac912k.<\/p><p>\n<b>Forward-Looking Statements (Safe Harbor)<\/b><\/p><p>\nThis press release contains forward-looking statements and financial targets regarding the full-year 2026 performance of ABL Diagnostics. Although the Company's management believes these projections are based on reasonable accounting, commercial, and order book assumptions as of the date of this release, these elements do not constitute guarantees of future performance. Actual audited results, to be published at a later stage, remain subject to risks and uncertainties, notably relating to year-end closing processes, the global supply chain, and IVDR regulatory compliance timelines.<\/p><p>\n<b>About ABL Diagnostics (ABLD)<\/b><\/p><p>\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p><ul class=\"bwlistdisc\">\n<li>\nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n<li>\nGenotyping by DNA sequencing \u2013 DeepChek<sup>\u00ae<\/sup>.<\/li>\n<\/ul><p>\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p><p>\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p><p>\n<b>An expanding portfolio of microbiology products:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n<li>\nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n<li>\nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n<li>\nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul><p>\n<b>Integrated Solutions<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nReal-time syndromic PCR tests<\/li>\n<li>\nNadis<sup>\u00ae<\/sup> \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n<li>\nMediaChek<sup>\u00ae<\/sup> \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul><p>\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABL Diagnostics SA<\/b><br\/>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\n<br\/>Headquarters : 72C route de Thionville - 57140 WOIPPY\n<br\/>552 064 933 R.C.S. METZ\n<br\/>\n<br\/>Tel : +33 (0)7 83 64 68 50\n<br\/>Email : <a  href=\"mailto:info@abldiagnostics.com\" rel=\"nofollow\" shape=\"rect\">info@abldiagnostics.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;esheet=54545433&amp;newsitemid=20260601791272&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;index=1&amp;md5=9030bc353a053527b25299a42fbc6587\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Full-year 2026 revenue target set at \u20ac12.27 million, delivering an exceptional +76.5% growth compared to 2025<\/p>\n<p>Historic shift in scale driven by the full-year impact of growth drivers (FTD Kits up +353%, Vela at \u20ac1.57m, and CDL at \u20ac2.48m)<\/p>\n<p>Strong com&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-14113","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14113"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14113\/revisions"}],"predecessor-version":[{"id":14114,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14113\/revisions\/14114"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}